Clinical Trials
62 trialsA Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Haplo Peripheral Blood Sct In GVHD Prevention
Massachusetts General Hospital
A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms
Janssen Research & Development, LLC
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving
Ipsen
CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms
Herlev Hospital
The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies
Memorial Sloan Kettering Cancer Center
Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
M.D. Anderson Cancer Center
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
National Cancer Institute (NCI)
Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
National Cancer Institute (NCI)
Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia
Case Comprehensive Cancer Center
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
University of Wisconsin, Madison
Interleukin-2 in Treating Patients With Myelodysplastic Syndrome
University of Washington
A Study in Myeloproliferative Disorders
Eli Lilly and Company
Phenylbutyrate and Tretinoin in Treating Patients With Hematologic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes
Ohio State University Comprehensive Cancer Center
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
California Cancer Consortium
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Massachusetts General Hospital
Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy
University of Louisville
Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Yale University
Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer
National Cancer Institute (NCI)
Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases
National Cancer Institute (NCI)
A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Seagen Inc.
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
Children's Oncology Group
STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders
Synta Pharmaceuticals Corp.
EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer
Indiana University
Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors
Indiana University
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
National Cancer Institute (NCI)
Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes
National Cancer Institute (NCI)
VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome
National Cancer Institute (NCI)
3-AP and Cytarabine in Treating Patients With Hematologic Cancer
National Cancer Institute (NCI)
Radiolabeled Monoclonal Antibody Therapy and Etoposide Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Myelodysplastic Syndrome or Refractory Leukemia
Memorial Sloan Kettering Cancer Center
Pyroxamide in Treating Patients With Advanced Cancer
Memorial Sloan Kettering Cancer Center
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
BCX-1777 in Treating Patients With Refractory Cancer
National Cancer Institute (NCI)
Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders
National Cancer Institute (NCI)
Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies
M.D. Anderson Cancer Center
Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant
National Cancer Institute (NCI)
Decitabine in Treating Patients With Melanoma or Other Advanced Cancer
National Cancer Institute (NCI)
Tipifarnib in Treating Patients With Advanced Hematologic Cancer
National Cancer Institute (NCI)
Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders
National Cancer Institute (NCI)
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction
National Cancer Institute (NCI)
Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Sodium Salicylate in Treating Patients With Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Chronic Lymphocytic Leukemia
Memorial Sloan Kettering Cancer Center
Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases
National Cancer Institute (NCI)
A Phase I Trial of ZIO-101 in Hematologic Cancers
Alaunos Therapeutics
Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Northwestern University
Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Northwestern University
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
National Institutes of Health Clinical Center (CC)